Expedition Therapeutics secured $115 million in Series B funding to advance EXPD-101, a DPP1 inhibitor targeting upstream inflammatory mechanisms in COPD rather than managing symptoms alone. The financing and Phase 2 trial launch reflect investor recognition that respiratory disease represents a significant frontier in longevity science, particularly therapies that address the biological drivers of progressive lung damage.
Key Points
- DPP1 inhibition targets early inflammatory cascade, not just airway opening
- First global randomized Phase 2 trial of DPP1 inhibitor in COPD
- Major investors recognize chronic inflammation as longevity-critical pathway
Longevity Analysis
COPD demonstrates how persistent, low-grade inflammation drives progressive tissue destruction independent of acute symptoms—a pattern central to multiple age-related conditions. Current therapies manage airflow obstruction without interrupting the underlying biological cascade that continues damaging lungs daily. Targeting DPP1 upstream represents a mechanistic shift from symptomatic management to interference with the inflammatory process itself, aligning with the emerging view that controlling chronic inflammatory signaling may slow or prevent disease progression rather than simply improving immediate function. This approach has implications beyond COPD for understanding how to intervene earlier in diseases where inflammation becomes pathological rather than protective.
Original published by Longevity.Technology, by Kyle Umipig.